

# MDCT Has High Accuracy in Real-World Setting

BY KERRI WACHTER  
Senior Writer

WASHINGTON — Multidetector CT angiography appears to be very accurate in diagnosing coronary artery disease even in less-than-ideal patients, according to data presented at the annual meeting of the Society of Cardiovascular Computed Tomography.

While published studies have shown impressive diagnostic sensitivity and specificity for 64-slice CT in the assessment of coronary artery disease (CAD), patients with irregular heartbeats or allergies to  $\beta$ -blockers have tended to be excluded. In addition, patients with histories of coronary disease or those with high calcium scores sometimes were excluded.

"MDCT studies that have been published ... have been highly selective of all the patients they have picked in order to determine the diagnostic accuracy of CT," said Dr. Amgad N. Makaryus, a cardiologist at North Shore University Hospital in Manhasset, New York.

Dr. Makaryus and his colleagues evaluated the accuracy of 64-detector scanning compared with coronary angiography in a real-world population, at North Shore University Hospital, a large tertiary care center.

**Calcified plaques appear enlarged because of partial-volume averaging effects and obscure the adjacent coronary lumen, which can lead to false-positive results.**

The facility is a referral center for hospitals on Long Island. Roughly 10,000 cardiac catheterizations are performed there yearly. In addition, 4,000-5,000 single-photon emission computed tomography myocardial perfusion studies are performed annually.

The study involved 1,818 consecutive patients who underwent coronary CT (64-detector).  $\beta$ -Blockers were used as much as possible.

Calcium channel blockers were used in patients who had contraindications to  $\beta$ -blockers.

The imaging protocol involved an 8- to 10-second breath hold with a 5- to 7-second image-acquisition time.

Overall, 17% of patients had a history of coronary disease; 10% had a history of atrial fibrillation or flutter. The mean heart rate during CT studies was roughly 58 beats per minute. The two most common indications were chest pain and abnormal stress test.

Specifically, the researchers assessed those patients who underwent invasive angiography based on their MDCT results. A total of 41 patients were referred for coronary angiography for 164 coronary arteries (410 coronary segments).

The mean patient age was 62 years (range 39-85 years) and the population was almost three-quarters male (73%). Stenosis of greater than 50% was considered significant.

On a per-vessel basis, the sensitivity of MDCT was 86% and specificity was 84%. The positive predictive value was 65% and the negative predictive value was 85%.

"Still we have this very high negative predictive value as has been seen in many of the prior studies," commented Dr. Makaryus. On a per-segment basis, the sensitivity of MDCT was 77% and specificity was 93%.

The positive predictive value was 61% and the negative predictive value was 97%.

Calcium is a particular problem in CT angiography. Calcified plaques appear enlarged (or bloomed) because of partial-volume averaging effects and obscure the adjacent coronary lumen. This effect can lead to false-positive results because the degree of stenosis is overestimated.

The mean calcium score in this group was 789. "More of the patients that had higher calcium scores actually had a disagreement between their CTA result and the invasive coronary angiogram," said

Dr. Makaryus. In other words, "our false positives tended to be those patients who had higher calcium scores, and this neared statistical significance [ $P = .059$ ]."

Irregular heart rate and motion artifacts also can be problematic in CT angiography, he said.

Dr. Makaryus, who disclosed that he had no significant conflicts of interest, was a postdoctoral clinical cardiovascular imaging fellow at New York-Presbyterian Hospital, New York, during 2006-2007. ■

The name **OMACOR**<sup>®</sup>  
omega-3-acid ethyl esters

is now **LOVAZA**<sup>™</sup>  
omega-3-acid ethyl esters

Reliant Pharmaceuticals, Inc. has taken this step at the request of the US Food and Drug Administration (FDA) and in response to a limited number of reports of prescribing and dispensing errors<sup>1</sup> due to similarity in name between the company's **OMACOR** capsules and Xanodyne Pharmaceuticals' **Amicar**<sup>®</sup> (aminocaproic acid).<sup>2</sup> The name change is intended to minimize the potential for such errors in the future.

References: 1. Data on file. Reliant Pharmaceuticals, Inc. 2. Amicar<sup>®</sup> is a registered trademark of Xanodyne Pharmaceuticals, Inc.

Please see brief summary of full prescribing information on the adjacent page.

PLEASE VISIT OUR WEB SITE AT [www.LOVAZA.com](http://www.LOVAZA.com)

**Reliant**  
PHARMACEUTICALS, INC.

Reliant Pharmaceuticals, Inc.  
Liberty Corner, NJ 07938

©2007 Reliant Pharmaceuticals, Inc.

RLOV-C1004

August 2007